Health
Novartis Set Its Growth Target Through 2031 at the Low End of Its Old Range
Bigger peak-sales promises for three key drugs did not spare the shares, which closed lower as investors weighed the patent cliffs still ahead.
Novartis on Thursday rolled its mid-term guidance forward to 2026-2031, setting net sales growth at a 5% constant-currency compound annual rate, the low end of its prior range.
The company set the outlook in Basel on Thursday. It featured the plan the same day at its Meet Novartis Management event in London.
The 5% figure sits at the low end of the range set last year. That range was 5% to 6% a year for 2025 to 2030, Reuters reported.
Beyond 2031, Novartis expects sustained mid-single-digit sales growth. The long-term line carries no end date and no single number.
The growth rate is stated in constant currency, which strips out exchange-rate moves. Core results and constant-currency figures are non-IFRS measures, the company noted.
Bigger peaks for three drugs
Kesimpta, the multiple sclerosis treatment, now carries peak sales guidance of $8 billion. That is up from $6 billion before Thursday.
Scemblix, for leukemia, rose from $4 billion to $5 billion. Leqvio, the cholesterol-lowering treatment, rose by the same step, to $5 billion.
The three upgrades follow a recent lift for Rhapsido, or remibrutinib. Its peak guidance now stands at $8 billion across three uses.
Those uses are chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis. Other indications carry additional multi-billion-dollar potential, the company said.
Nine de-risked, in-market assets now sit in a $3 billion to $10 billion peak-sales band. The band describes potential at a drug's peak year, not dated revenue.
The nine are Kisqali, Rhapsido, Cosentyx, Kesimpta and Pluvicto. Scemblix, Leqvio, the Zolgensma group and Fabhalta complete the list.
The Zolgensma group covers Zolgensma and Itvisma. Each asset on the list is already on the market.
Chief Executive Vas Narasimhan framed 2026 as a stress year the company still expects to grow through. He said that "in 2026 we expect to grow through the largest loss-of-exclusivity impact in our history."
Why investors marked the shares down
Novartis shares closed down 3.2% in Zurich on Thursday, dpa-AFX reported. The new target fell short of investor expectations, Reuters reported.
The caution has a dated cause. Two major late-stage setbacks this year led to a $2.2 billion writedown in the third quarter, Reuters reported.
Patent expiries frame the rest of the decade. Heart drug Entresto already faces generic competition and is set to lose $4 billion in sales this year, Reuters reported.
After 2030, the pressure moves to two best sellers. Kisqali and Cosentyx will then face competition from cheaper rivals, Reuters reported.
Analysts expect sales growth of about 4.5% a year from 2026 to 2031. That consensus sits close to the 5% target, with growth slowing after 2030, Reuters reported.
The stock is still up 16% this year, Reuters reported. Thursday's fall trimmed a strong year rather than reversing it.
Daniel Bolanowski of Arctic Asset Management called the selloff modest. He traced it to an "absence of anything revolutionary" in the guidance, Reuters reported.
His concern sits beyond the guide itself. It is the years after the next five, which he said the company has not fully addressed, Reuters reported.
Growth promised from within
Most growth beyond 2031 will come from medicines developed internally, Narasimhan said. The mid-term targets assume no large acquisitions, Reuters reported.
"We would expect the contribution of M&A and BD (business development) to be consistent with what we've done in the past," Narasimhan said.
The pipeline behind that promise is counted in the guide. Novartis expects more than thirty-five potentially submission-enabling readouts through 2031.
It also counts more than thirty potential high-value pipeline assets. Ten late-stage assets carry multi-billion-dollar peak-sales guidance.
One setback was del-desiran, from the $12 billion Avidity deal. Novartis still expects multibillion-dollar peak sales from it, and an analysis is ongoing, Reuters reported.
What remains unknown
What remains unknown starts with delivery against the new bar. Novartis has not shown how the 5% path splits by year or by brand.
Whether the three upgraded peaks arrive on the company's timetable is unknown. Peak sales are potential at the top year, not a dated forecast.
How the post-2030 competition for Kisqali and Cosentyx will land is also unknown. So is whether internal growth alone can carry the years beyond 2031.
The tests that come next
The first test is 2026 itself. Narasimhan has promised growth through the largest exclusivity loss in company history.
The second test is the margin path. Core margin must climb back to 40% or more by 2029 while the guide holds.
The third test is the pipeline count. The promised readouts through 2031 must land, because each miss reprices the long term.
Sources & evidence
Source checked3 sources · 11 figures
Figure receipts
Sources
Sources used for this piece.
As of Thursday, Nov. 19, 2026.

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

